BRIEF published on 09/15/2026 at 15:40, 2 months 5 days ago Revive Therapeutics vise à élargir son portefeuille de produits à base de bucillamine. Propriété Intellectuelle Maladies Orphelines Contre-mesures Médicales Bucillamine Partenariats Gouvernementaux
BRIEF published on 09/15/2026 at 15:40, 2 months 5 days ago Revive Therapeutics Aims to Expand Bucillamine Portfolio Intellectual Property Orphan Diseases Medical Countermeasures Government Partnerships Bucillamine
PRESS RELEASE published on 09/15/2026 at 15:35, 2 months 5 days ago Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases Revive Therapeutics Ltd. outlines strategy to build protected bucillamine franchise for medical countermeasures, rare diseases, and government preparedness programs Rare Diseases Medical Countermeasures Revive Therapeutics Ltd. Bucillamine Franchise Government Preparedness
BRIEF published on 08/19/2026 at 20:40, 3 months 1 day ago Revive Therapeutics Proposes Shares for Debt Settlement Debt Settlement Canadian Securities Exchange Shares Issuance Revive Therapeutics Biodefense Research
BRIEF published on 08/19/2026 at 20:40, 3 months 1 day ago Revive Therapeutics propose des actions en échange du règlement de sa dette Émission D'actions Règlement De Dettes Bourse Canadienne Des Valeurs Mobilières Revive Therapeutics Recherche En Biodéfense
PRESS RELEASE published on 08/19/2026 at 20:35, 3 months 1 day ago Revive Therapeutics Announces Proposed Shares for Debt Settlement Revive Therapeutics Ltd. announces proposed debt settlement by issuing Settlement Shares to settle outstanding trade payables. Subject to CSE approval Debt Settlement Settlement Shares CSE Approval Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/19/2026 at 14:45, 3 months 1 day ago Revive Therapeutics fait progresser sa stratégie de biodéfense avec la bucillamine Biodefense Contre-mesures Médicales Préparation Aux Pandémies Bucillamine Partenariats Gouvernementaux
BRIEF published on 08/19/2026 at 14:45, 3 months 1 day ago Revive Therapeutics Advances Biodefence Strategy with Bucillamine Medical Countermeasures Pandemic Preparedness Government Partnerships Bucillamine Biodefence
PRESS RELEASE published on 08/19/2026 at 14:40, 3 months 1 day ago Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Revive plans to expand bucillamine use in biodefence with positive DRDC findings, government opportunities, and complementary therapies, focusing on medical countermeasures Bucillamine Biodefence Revive DRDC Government Opportunities
BRIEF published on 08/15/2026 at 00:55, 3 months 5 days ago Revive Therapeutics Grants 15.5 Million Stock Options Stock Options Life Sciences Biodefense Pandemic Preparedness Revive Therapeutics
Published on 11/20/2026 at 15:00, 5 hours 48 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 5 hours 58 minutes ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 6 hours 48 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 7 hours 18 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 7 hours 18 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 19:26, 1 hour 22 minutes ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 hour 44 minutes ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:18, 2 hours 29 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary figures for FY 2025/26: Order intake above previous year, free cash flow positive; EBIT below guidance due to additional project costs in the gH2 segment
Published on 11/20/2026 at 17:35, 3 hours 13 minutes ago Guangzhou Nansha: GBA's strategic pivot for Asia-Pacific trade
Published on 11/20/2026 at 18:34, 2 hours 13 minutes ago Déclaration hebdomadaire d'opérations effectuées du 16 au 20 novembre 2026
Published on 11/20/2026 at 18:34, 2 hours 13 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 3 hours 13 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 16 au 20 novembre 2026
Published on 11/20/2026 at 17:35, 3 hours 13 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026